Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
SMARCA2/4-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "SMARCA2/4-IN-1" in MCE Product Catalog:
Cat. No.: HY-161884
CAS No.: 76947-79-0
Target:
Research Areas:
SMARCA2/4-IN-1 (compound 1) is a potent SMARCA2 inhibitor with IC50 values of 3.8, 1.7 µM for SMARCA2, SMARCA4, respectively .
Cat. No.: HY-175756
CAS No.: 2901804-87-1
Target:
Research Areas:
SMARCA2/4 degrader-1 is a SMARCA2/4 molecular glue degrader with a DCAF16 EC50 of 110 nM. SMARCA2/4 degrader-1 covalently adducts at cysteine to form a ternary complex with SMARCA2/4 and recruits CUL4 DCAF16 and CRL1 FBXO22 E3 ligase complexes. SMARCA2/4 degrader-1 induces ubiquitination and proteasomal degradation of SMARCA2/4. SMARCA2/4 degrader-1 can be used for research of SMARCA4-deficient malignancies, non-small cell lung cancer (NSCLC), and colorectal cancer .
Cat. No.: HY-163152
CAS No.: 2378051-80-8
Target:
Research Areas:
PROTAC BRM degrader-1 is a VHL-recruiting PROTAC degrader that exhibits higher selectivity for the degradation of SMARCA2 (BRM) over its highly homologous protein SMARCA4 (BRG1). The KD values of PROTAC BRM degrader-1 for BRM and BRG1 are 72 nM and 108 nM, respectively. PROTAC BRM degrader-1 can be used in studies related to selective SMARCA2 degradation, SWI/SNF function, and SMARCA4-mutant non-small cell lung cancer .
Cat. No.: HY-161885
CAS No.: 2270875-79-9
Target:
Research Areas:
SMARCA2-IN-6 is a SMARCA2 and SMARCA4 inhibitor, with an IC50 value of <0.005 μM for both SMARCA2 and SMARCA4. SMARCA2-IN-6 exerts anticancer activity against BRG1-mutant melanoma. SMARCA2-IN-6 can be used for research related to Brg1/Smarca4-mutant cancers .
Cat. No.: HY-171774
CAS No.: 1997321-76-2
Research Areas:
PBRM1/SMARCA2,4-ligand-1 (Compound 4) is a Ligand for Target Protein for PROTAC that binds to PBRM1, SMARCA2, and SMARCA4. PBRM1/SMARCA2,4-ligand-1 is a potent SMARCA4 bromodomain inhibitor. PBRM1/SMARCA2,4-ligand-1 can be used to synthesize PROTAC AU-24118 (HY-163410) .
Cat. No.: HY-159452
CAS No.: 2568273-68-5
SMARCA2/4-degrader-1 (compound I-430) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC50s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .
Cat. No.: HY-174237
Target:
Research Areas:
PBRM1/SMARCA2,4 binder-1 (Compound 17) is a binder of PBRM1, SMARCA2, and SMARCA4 (IC50: 0.083, 0.153, and 0.046 μM, respectively) .
Cat. No.: HY-161889
CAS No.: 880811-10-9
Target:
Research Areas:
DCSM06-05 is a potent SMARCA2-BRD inhibitor with an IC50 value of 9 µM, a Kd value of 22.4 µM .
Cat. No.: HY-159592
Target:
Research Areas:
Piperazine-Pyrimidine-Cyclohexane-COOEt is a PROTAC linker. Piperazine-Pyrimidine-Cyclohexane-COOEt can be used in the synthesis of PROTAC SMARCA2/4-degrader-1 (HY-159452) .
Cat. No.: HY-162791
Target:
Research Areas:
(1s,4s)-C1-Piperidine-C1-cyclohexane-C1 is a PROTAC linker. (1s,4s)-C1-Piperidine-C1-cyclohexane-C1 can be used to synthesize PROTAC SMARCA2/4-degrader-33 (HY-162741) .
Cat. No.: HY-182987
Research Areas:
SMARCA2/SMARCA4 ligand-1 is a SMARCA2/SMARCA4 ligand with KD values of 1.2 and 10.3 nM. SMARCA2/SMARCA4 ligand-1 binds SMARCA2/4 bromodomain via hydrogen bonds with asparagine and tyrosine residues, and a salt bridge with a glutamate residue. SMARCA2/SMARCA4 ligand-1 shows antiproliferative activity against cancer cells. SMARCA2/SMARCA4 ligand-1 can be used for the research of cancer, such as smarca4 mutant nonsmall cell lung cancer .
Cat. No.: HY-159593
Research Areas:
Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo is an E3 Ligase Ligand-Linker Conjugate. Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo can be used to synthesize PROTAC SMARCA2/4-degrader-1 (HY-159452) .
Cat. No.: HY-185075
CAS No.: 3008577-34-9
Synonyms: LY4050784
Target:
Research Areas:
FHD-909 (LY4050784) is an orally active and selective SMARCA2 (BRM) ATPase inhibitor. FHD-909 potently inhibits purified BRM ATPase with an IC50 of 0.0025 μM and exhibits 35.69-fold selectivity for BRM over purified SMARCA4 (BRG1) ATPase. FHD-909 induces synthetic lethality, suppresses cell proliferation, modulates target gene expression, and achieves remarkable tumor growth inhibition and regression in SMARCA4-mutant cancer cells and xenograft models. FHD-909 can be used for the research of SMARCA4/BRG1-mutant cancers, advanced solid tumors, and BAF complex-related disorders .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
